Evaluation of the treatment effectiveness in children with coronavirus infection.

Objective: Aim: To study and analyze the treatment effectiveness in children with identified Coronavirus infection..

Patients And Methods: Materials and Methods: included the treatment and analysis of the study results of of children (n=68, aged 14.

RESPIRATORY MICROBIOME AND ITS RELATIONSHIP WITH INFLAMMATORY MARKERS.

Objective: The aim: This study aims to investigate and analyze the microbiome of the nasopharyngeal zone in acute respiratory infections (ARI) and their relationship with inflammatory markers.

Patients And Methods: Materials and methods: Examination of 112 children (10-14 years old) with acute respiratory infections (ARI) of the upper respiratory tract was carried out. The control group consisted of 25 healthy children identical in age and examination parameters.

ASSESSMENT OF CARDIOVASCULAR DISEASE RISK FACTORS IN PATIENTS WITH CORONARY HEART DISEASE COMBINED WITH NONALCOHOLIC FATTY LIVER DISEASE.

Objective: The aim: To study the risk factors of cardiovascular diseases in patients with coronary heart disease with stable angina pectoris II functional class in combi¬nation with NAFLD.

Patients And Methods: Materials and methods: The study included 245 patients with a diagnosis of CHD, stable angina pectoris II functional class (FC), who were being treated at the Communal Nonprofit Enterprise «Central City Clinical Hospital» of Uzhhorod City Council. We singled out 2 groups of patients: group 1 (n=145) - patients with CHD with stable angina pectoris II FC in combination with NAFLD and group 2 (n=100) - patients with CHD with stable angina pectoris II FC.

THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Objective: The aim: Was increase the effectiveness of treatment in patients with non-alcoholic fatty liver disease (NAFLD) comorbid with chronic obstructive pulmonary disease (COPD) by using ursodeoxycholic acid (UDCA) in combination with ademethionine.

Patients And Methods: Materials and methods: Under observation was 98 patients with a diagnosis of NAFLD and COPD group II or their combination. Patients were divided into 3 groups: 1 (n = 36) - COPD + NASH - in addition to standard COPD therapy received UDCA 15 mg / kg / day - 6 months and ademethionine 1000 mg IV once a day for 10 days, followed by oral administration of 500 mg 2 times per day - 20 days, and group 2 (n = 32) - COPD + hepatic steatosis - in addition to standard therapy - UDCA 15 mg / kg / day - 6 months.